Please use this identifier to cite or link to this item:
|Title:||Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial|
|Authors:||Kefford, Richard (Rick)|
Gangadhar, Tara C.
Hodi, F. Stephen
Joseph, Richard W.
Joshua, Anthony M.
Wolchok, Jedd D.
Western Clinical School: Westmead Millennium Institute
|Publisher:||The Lancet Publishing Group|
|Citation:||Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117|
|Department/Unit/Centre:||Western Clinical School: Westmead Millennium Institute|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.